Year: 2017
Type: editorial
Abstract: Owing to their unprecedented success in the management of advanced or metastatic disease, immune checkpoint blockers (ICBs) are being elevated to the rank of standard-of-care for patients affected ...
Source: OncoImmunology
Authors: Claire Vanpouille-Box, Lorenzo Galluzzi
Institutions: Weill Cornell Medicine, Université Paris Descartes
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
Awards: G4119534169, G8632625050
OpenAlex ID: W2741376942